董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joseph B. Saluri | 男 | Director | 50 | 未披露 | 未持股 | 2017-03-31 |
| Paolo Pucci | 男 | Director | 55 | 21.97万美元 | 未持股 | 2017-03-31 |
| Charles J. Link, Jr. | 男 | Chairman of the Board and Chief Executive and Scientific Officer | 59 | 670.48万美元 | 未持股 | 2017-03-31 |
| Nicholas N. Vahanian | 男 | Director | 49 | 444.99万美元 | 未持股 | 2017-03-31 |
| Thomas A. Raffin | 男 | Director | 70 | 24.93万美元 | 未持股 | 2017-03-31 |
| Ernest J. Talarico, III | 男 | Director | 46 | 22.51万美元 | 未持股 | 2017-03-31 |
| Paul R. Edick | 男 | Director | 61 | 22.11万美元 | 未持股 | 2017-03-31 |
| Lota S. Zoth | 女 | Director | 57 | 23.16万美元 | 未持股 | 2017-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John B. Henneman, III | 男 | Chief Financial Officer and Secretary | 63 | 361.88万美元 | 未持股 | 2017-03-31 |
| Charles J. Link, Jr. | 男 | Chairman of the Board and Chief Executive and Scientific Officer | 59 | 670.48万美元 | 未持股 | 2017-03-31 |
| Nicholas N. Vahanian | 男 | President and Chief Medical Officer | 49 | 444.99万美元 | 未持股 | 2017-03-31 |
| Brian Wiley | 男 | Chief Commercial Officer | 57 | 158.07万美元 | 未持股 | 2017-03-31 |
董事简历
中英对照 | 中文 | 英文- Joseph B. Saluri
-
Joseph B. Saluri，他一直担任Zevra Therapeutics, Inc.的董事。公司成立于2014年1月。自2018年8月以来，Saluri先生一直担任BlueAllele, LLC（位于明尼苏达州奥克代尔的初创生物技术公司）的首席执行官兼董事会主席。2017年6月至2018年3月，他曾担任Calyxt, Inc.的总法律顾问兼执行副总裁。在加入Calyxt, Inc.之前，他曾担任Stine Seed Company及其附属公司的总法律顾问（1999年7月至2017年3月）。1993年6月至1999年6月，他在爱荷华州得梅因和英国伦敦的Nicholas Critelli Associates, PC担任律师和律师。2010年5月至2017年7月，他担任Newlink Genetics Corporation（一家上市生物制药公司）的董事。他持有Drake University Law School的法学博士学位，Drake University Law School的工商管理学士学位，Drake University的工商管理学士学位。
Joseph B. Saluri,has served as a director of Zevra Therapeutics, Inc. Company since January 2014. Since August 2018, Mr. Saluri has served as the chief executive officer and chairman of the board of BlueAllele, LLC, a start-up biotechnology company located in Oakdale, Minnesota. Mr. Saluri previously served as general counsel and executive vice president for Calyxt, Inc. from June 2017 to March 2018. Prior to his employment with Calyxt, Inc., Mr. Saluri served as general counsel for Stine Seed Company and its affiliates from July 1999 to March 2017. Mr. Saluri practiced as an attorney and solicitor at law with Nicholas Critelli Associates, PC, in Des Moines, Iowa and London, England from June 1993 to June 1999. Mr. Saluri served as a director of Newlink Genetics Corporation, a public biopharmaceutical company from May 2010 to July 2017. Mr. Saluri received his J.D. degree from Drake University Law School and his B.S.B.A. degree from Drake University Law School and his B.S.B.A. degree from Drake University. - Joseph B. Saluri，他一直担任Zevra Therapeutics, Inc.的董事。公司成立于2014年1月。自2018年8月以来，Saluri先生一直担任BlueAllele, LLC（位于明尼苏达州奥克代尔的初创生物技术公司）的首席执行官兼董事会主席。2017年6月至2018年3月，他曾担任Calyxt, Inc.的总法律顾问兼执行副总裁。在加入Calyxt, Inc.之前，他曾担任Stine Seed Company及其附属公司的总法律顾问（1999年7月至2017年3月）。1993年6月至1999年6月，他在爱荷华州得梅因和英国伦敦的Nicholas Critelli Associates, PC担任律师和律师。2010年5月至2017年7月，他担任Newlink Genetics Corporation（一家上市生物制药公司）的董事。他持有Drake University Law School的法学博士学位，Drake University Law School的工商管理学士学位，Drake University的工商管理学士学位。
- Joseph B. Saluri,has served as a director of Zevra Therapeutics, Inc. Company since January 2014. Since August 2018, Mr. Saluri has served as the chief executive officer and chairman of the board of BlueAllele, LLC, a start-up biotechnology company located in Oakdale, Minnesota. Mr. Saluri previously served as general counsel and executive vice president for Calyxt, Inc. from June 2017 to March 2018. Prior to his employment with Calyxt, Inc., Mr. Saluri served as general counsel for Stine Seed Company and its affiliates from July 1999 to March 2017. Mr. Saluri practiced as an attorney and solicitor at law with Nicholas Critelli Associates, PC, in Des Moines, Iowa and London, England from June 1993 to June 1999. Mr. Saluri served as a director of Newlink Genetics Corporation, a public biopharmaceutical company from May 2010 to July 2017. Mr. Saluri received his J.D. degree from Drake University Law School and his B.S.B.A. degree from Drake University Law School and his B.S.B.A. degree from Drake University.
- Paolo Pucci
-
Paolo Pucci，2008年6月，他从Bayer A.G。跳槽到ArQule，并担任首席行政官和董事会成员，他在Bayer A.G。担任高级副总裁和Bayer-Schering全球肿瘤治疗制药商业机构总裁；此前，他是Bayer药厂的全球性专业经营单位的高级副总裁，美国制药业务的总裁和Bayer制药公司的全球管理委员会成员；在Bayer，他负责Nexavar sorafenib（一种用于治疗肝脏和肾脏癌的口服多激酶抑制剂）相关业务。这些活动包括临床开发、监管部门的审查、企业联盟管理、产品发布和市场营销。2001年，他加入Bayer，担任意大利地区的制药业务。在加入Bayer之前，他在Eli Lilly任职，并且职务越来越高，后成为Eli Lilly Sweden AB的管理董事。在Lilly工作的时候，他主要负责业务、销售、市场营销和战略规划。2011年11月，他被任命为Dyax Corp的董事，目前他在Dyax Corp担任独立董事、审核委员会成员和管理、提名委员会主席。2013年4月，他被任命为Algeta ASA（位于挪威奥斯陆的肿瘤研究公司，）董事会成员，后担任独立董事和审核委员会成员直到Algeta被Bayer A.G收购。他获有芝加哥大学的工商管理硕士学位，还是意大利那不勒斯大学研究生，是意大利特许Dottore Commercialista。
Paolo Pucci,From 2008 until its acquisition by Merck & Co. in January 2020, Mr. Pucci served as the Chief Executive Officer of ArQule, Inc., a biopharmaceutical oncology and rare diseases company engaged in the research and development of targeted therapeutics. Before joining ArQule, Inc., Mr. Pucci worked at Bayer AG from 2001 to 2008, where he served in a number of leadership capacities, including President of the Oncology & Global Specialty Medicines Business Units, and was a member of the Bayer AG Pharmaceuticals Global Management Committee. Before Bayer AG, Mr. Pucci held positions of increasing responsibility with Eli Lilly & Co. from July 1991 to April 2001, culminating with his appointment as Managing Director, Eli Lilly Sweden AB. Mr. Pucci currently serves on the boards of directors of West Pharmaceuticals Services, Inc. and Merus N.V., each of which are publicly listed companies. Additionally, Mr. Pucci previously served as Chair of the Audit Committee of Merus N.V. He is also a director at the privately held company AION Healthspan and in January 2025, he was appointed as an independent Non-Executive Director to the board of Chiesi Farmaceutici, a privately held Italian biopharmaceutical group. Mr. Pucci previously served on the boards of directors of ArQule, Inc., Algeta ASA, until its acquisition by Bayer AG, Dyax Inc., until its acquisition by Shire plc, NewLink Genetics Inc. and Trillium Therapeutics, Inc., until its acquisition by Pfizer Inc. Mr. Pucci earned an M.S. in economics and accounting from Università degli Study di Napoli Federico II and an M.B.A. in marketing and finance from the University of Chicago. - Paolo Pucci，2008年6月，他从Bayer A.G。跳槽到ArQule，并担任首席行政官和董事会成员，他在Bayer A.G。担任高级副总裁和Bayer-Schering全球肿瘤治疗制药商业机构总裁；此前，他是Bayer药厂的全球性专业经营单位的高级副总裁，美国制药业务的总裁和Bayer制药公司的全球管理委员会成员；在Bayer，他负责Nexavar sorafenib（一种用于治疗肝脏和肾脏癌的口服多激酶抑制剂）相关业务。这些活动包括临床开发、监管部门的审查、企业联盟管理、产品发布和市场营销。2001年，他加入Bayer，担任意大利地区的制药业务。在加入Bayer之前，他在Eli Lilly任职，并且职务越来越高，后成为Eli Lilly Sweden AB的管理董事。在Lilly工作的时候，他主要负责业务、销售、市场营销和战略规划。2011年11月，他被任命为Dyax Corp的董事，目前他在Dyax Corp担任独立董事、审核委员会成员和管理、提名委员会主席。2013年4月，他被任命为Algeta ASA（位于挪威奥斯陆的肿瘤研究公司，）董事会成员，后担任独立董事和审核委员会成员直到Algeta被Bayer A.G收购。他获有芝加哥大学的工商管理硕士学位，还是意大利那不勒斯大学研究生，是意大利特许Dottore Commercialista。
- Paolo Pucci,From 2008 until its acquisition by Merck & Co. in January 2020, Mr. Pucci served as the Chief Executive Officer of ArQule, Inc., a biopharmaceutical oncology and rare diseases company engaged in the research and development of targeted therapeutics. Before joining ArQule, Inc., Mr. Pucci worked at Bayer AG from 2001 to 2008, where he served in a number of leadership capacities, including President of the Oncology & Global Specialty Medicines Business Units, and was a member of the Bayer AG Pharmaceuticals Global Management Committee. Before Bayer AG, Mr. Pucci held positions of increasing responsibility with Eli Lilly & Co. from July 1991 to April 2001, culminating with his appointment as Managing Director, Eli Lilly Sweden AB. Mr. Pucci currently serves on the boards of directors of West Pharmaceuticals Services, Inc. and Merus N.V., each of which are publicly listed companies. Additionally, Mr. Pucci previously served as Chair of the Audit Committee of Merus N.V. He is also a director at the privately held company AION Healthspan and in January 2025, he was appointed as an independent Non-Executive Director to the board of Chiesi Farmaceutici, a privately held Italian biopharmaceutical group. Mr. Pucci previously served on the boards of directors of ArQule, Inc., Algeta ASA, until its acquisition by Bayer AG, Dyax Inc., until its acquisition by Shire plc, NewLink Genetics Inc. and Trillium Therapeutics, Inc., until its acquisition by Pfizer Inc. Mr. Pucci earned an M.S. in economics and accounting from Università degli Study di Napoli Federico II and an M.B.A. in marketing and finance from the University of Chicago.
- Charles J. Link, Jr.
-
Charles J. Link, Jr.，1999年创办NewLink Genetics Corporation，并担任董事长、首席科学官。2001-2009，他担任其总裁；2003年起，担任首席执行官。他从2005年起，担任BioProtection Systems Corporation的总裁、首席执行官；2005-2009，担任首席科学官。1995-2013，他是Medical Oncology and Hematology Associates of Iowa的执业肿瘤科医生。1995-2003，他担任John Stoddard Cancer Research Institute的主任，他是该机构的联合创始人。1988-1991，他是National Cancer Institute（NCI）和National Institutes of Health（NIH）的医学肿瘤临床研究员。1977-1980，他就读于U.S. Air Force Academy。他获得了Stanford University的学士学位、Stanford University School of Medicine的医学博士学位；他是American Board of Internal Medicine注册的内科医生，之前注册为肿瘤医学。
Charles J. Link, Jr., M.D., founded NewLink Genetics Corporation in 1999 and has served as Chairman of Lumos Pharma, Inc. Board and Lumos Pharma, Inc.Chief Scientific Officer since inception in 1999.He served as President from 2001 to 2009 and has served as Chief Executive Officer since 2003.From 1995 to 2013 Dr. Link was a practicing oncologist at the Medical Oncology and Hematology Associates of Iowa.From 1995 to 2003 Dr. Link served as the Director of the John Stoddard Cancer Research Institute, which he co-founded.Dr. Link served as a Medical Oncology Clinical Fellow at the National Cancer Institute and National Institutes of Health from 1988 to 1991.Dr. Link attended the U.S. Air Force Academy from 1977 to 1980.Dr. Link holds a B.A. from Stanford University, an M.D. from Stanford University School of Medicine and is certified in Internal Medicine by the American Board of Internal Medicine and has previously been certified in Medical Oncology. - Charles J. Link, Jr.，1999年创办NewLink Genetics Corporation，并担任董事长、首席科学官。2001-2009，他担任其总裁；2003年起，担任首席执行官。他从2005年起，担任BioProtection Systems Corporation的总裁、首席执行官；2005-2009，担任首席科学官。1995-2013，他是Medical Oncology and Hematology Associates of Iowa的执业肿瘤科医生。1995-2003，他担任John Stoddard Cancer Research Institute的主任，他是该机构的联合创始人。1988-1991，他是National Cancer Institute（NCI）和National Institutes of Health（NIH）的医学肿瘤临床研究员。1977-1980，他就读于U.S. Air Force Academy。他获得了Stanford University的学士学位、Stanford University School of Medicine的医学博士学位；他是American Board of Internal Medicine注册的内科医生，之前注册为肿瘤医学。
- Charles J. Link, Jr., M.D., founded NewLink Genetics Corporation in 1999 and has served as Chairman of Lumos Pharma, Inc. Board and Lumos Pharma, Inc.Chief Scientific Officer since inception in 1999.He served as President from 2001 to 2009 and has served as Chief Executive Officer since 2003.From 1995 to 2013 Dr. Link was a practicing oncologist at the Medical Oncology and Hematology Associates of Iowa.From 1995 to 2003 Dr. Link served as the Director of the John Stoddard Cancer Research Institute, which he co-founded.Dr. Link served as a Medical Oncology Clinical Fellow at the National Cancer Institute and National Institutes of Health from 1988 to 1991.Dr. Link attended the U.S. Air Force Academy from 1977 to 1980.Dr. Link holds a B.A. from Stanford University, an M.D. from Stanford University School of Medicine and is certified in Internal Medicine by the American Board of Internal Medicine and has previously been certified in Medical Oncology.
- Nicholas N. Vahanian
-
Nicholas N. Vahanian，NewLink Genetics Corporation的创始人之一，在临床试验设计和药物开发方面有着丰富的经验。2009年起，他担任本公司的总裁、首席医务官；此前，曾担任首席运营官。他是BioProtection Systems Corporation的联合创始人之一，曾担任其首席医务官。他领导了超急性胰脏胰腺癌新药疫苗项目，其中包括IMPRESS试验，这是美国史上胰腺癌切除患者辅助治疗研究的最大规模的试验。他在National Cancer Institute （NCI）开始研究工作，后来任职于National Center for Human Genome Research Institute和 National Institute of Health。他曾就读于St Bartholomew’s 和 Royal London Hospital Medical College，获得了医学学位；后来在John Stoddard Cancer Research Institute完成了分子肿瘤学研究员工作。他获得了Virginia Commonwealth University的生物学学士学位、University of Notre Dame的工商管理硕士学位。
Nicholas N. Vahanian a co-founder of our Company, has served as President and Chief Medical Officer of our Company since 2009 and previously served as Chief Operations Officer. Dr. Vahanian began his research career at the National Cancer Institute and subsequently worked at the National Center for Human Genome Research Institute, National Institute of Health. He attended St Bartholomew’s and Royal London Hospital Medical College and earned his Medical Degree and subsequently completed a Molecular Oncology Fellowship at the John Stoddard Cancer Research Institute. Dr. Vahanian holds a B.S. in Biology from Virginia Commonwealth University and an MBA from the University of Notre Dame. - Nicholas N. Vahanian，NewLink Genetics Corporation的创始人之一，在临床试验设计和药物开发方面有着丰富的经验。2009年起，他担任本公司的总裁、首席医务官；此前，曾担任首席运营官。他是BioProtection Systems Corporation的联合创始人之一，曾担任其首席医务官。他领导了超急性胰脏胰腺癌新药疫苗项目，其中包括IMPRESS试验，这是美国史上胰腺癌切除患者辅助治疗研究的最大规模的试验。他在National Cancer Institute （NCI）开始研究工作，后来任职于National Center for Human Genome Research Institute和 National Institute of Health。他曾就读于St Bartholomew’s 和 Royal London Hospital Medical College，获得了医学学位；后来在John Stoddard Cancer Research Institute完成了分子肿瘤学研究员工作。他获得了Virginia Commonwealth University的生物学学士学位、University of Notre Dame的工商管理硕士学位。
- Nicholas N. Vahanian a co-founder of our Company, has served as President and Chief Medical Officer of our Company since 2009 and previously served as Chief Operations Officer. Dr. Vahanian began his research career at the National Cancer Institute and subsequently worked at the National Center for Human Genome Research Institute, National Institute of Health. He attended St Bartholomew’s and Royal London Hospital Medical College and earned his Medical Degree and subsequently completed a Molecular Oncology Fellowship at the John Stoddard Cancer Research Institute. Dr. Vahanian holds a B.S. in Biology from Virginia Commonwealth University and an MBA from the University of Notre Dame.
- Thomas A. Raffin
-
Thomas A. Raffin，1999年起担任本公司董事；现为首席独立董事。他在Stanford University School of Medicine有着30年的教学经验，他是该校的医学和生物医学伦理Colleen and Robert Haas Professor Emeritus。过去的20年里，他广泛地任职于医疗保健和医疗器械行业，并担任多家公司的顾问，包括：Cell Therapeutics Inc.（1993-1997）、Broncus Technologies （1997-2004）、iMedica （1998-2002）、Inhale Technologies （1998-2001）。1996年，他参与创办了Rigel Pharmaceuticals，现已上市。2001年，他参与创办了Telegraph Hill Partners，这是位于旧金山的生命科学行业私募投资公司，现为其普通合伙人。他是Telegraph Hill Partners多个投资组合公司的董事：AngioScore、Confirma、Freedom Innovations、LDR， 和 PneumRx；他与Estech 和 Vidacare也有很近的工作关系。他获得了Stanford University的学士学位、Stanford University School of Medicine的医学博士学位；在位于马萨诸塞州波士顿的Peter Bent Brigham Hospital （现Brigham and Women's Hospital）完成住院实习。
Thomas A. Raffin has served as a member of our Board since 1999 and is currently our Board’s Lead Independent Director. Dr. Raffin has spent 30 years on the faculty at Stanford University School of Medicine, where he is the Colleen and Robert Haas Professor Emeritus of Medicine and Biomedical Ethics. Over the past two decades, Dr. Raffin has worked extensively in the healthcare and medical device business sectors and was an advisor to Cell Therapeutics Inc. from 1993 to 1997 Broncus Technologies from 1997 to 2004 iMedica from 1998 to 2002 and Inhale Technologies from 1998 to 2001. He co-founded Rigel Pharmaceuticals, a publicly traded company, in 1996. In 2001 he co-founded Telegraph Hill Partners, a San Francisco life sciences private equity firm as a General Partner. Dr. Raffin has been a director of the following Telegraph Hill Partners private portfolio companies: AngioScore, Confirma, Freedom Innovations, LDR Holding Corporation, Magstim and PneumRx; and he has worked closely with Estech and Vidacare. Dr. Raffin received a B.A. from Stanford University and an M.D. from Stanford University School of Medicine and did his medical residency at the Peter Bent Brigham Hospital now Brigham and Women's Hospital in Boston, MA. - Thomas A. Raffin，1999年起担任本公司董事；现为首席独立董事。他在Stanford University School of Medicine有着30年的教学经验，他是该校的医学和生物医学伦理Colleen and Robert Haas Professor Emeritus。过去的20年里，他广泛地任职于医疗保健和医疗器械行业，并担任多家公司的顾问，包括：Cell Therapeutics Inc.（1993-1997）、Broncus Technologies （1997-2004）、iMedica （1998-2002）、Inhale Technologies （1998-2001）。1996年，他参与创办了Rigel Pharmaceuticals，现已上市。2001年，他参与创办了Telegraph Hill Partners，这是位于旧金山的生命科学行业私募投资公司，现为其普通合伙人。他是Telegraph Hill Partners多个投资组合公司的董事：AngioScore、Confirma、Freedom Innovations、LDR， 和 PneumRx；他与Estech 和 Vidacare也有很近的工作关系。他获得了Stanford University的学士学位、Stanford University School of Medicine的医学博士学位；在位于马萨诸塞州波士顿的Peter Bent Brigham Hospital （现Brigham and Women's Hospital）完成住院实习。
- Thomas A. Raffin has served as a member of our Board since 1999 and is currently our Board’s Lead Independent Director. Dr. Raffin has spent 30 years on the faculty at Stanford University School of Medicine, where he is the Colleen and Robert Haas Professor Emeritus of Medicine and Biomedical Ethics. Over the past two decades, Dr. Raffin has worked extensively in the healthcare and medical device business sectors and was an advisor to Cell Therapeutics Inc. from 1993 to 1997 Broncus Technologies from 1997 to 2004 iMedica from 1998 to 2002 and Inhale Technologies from 1998 to 2001. He co-founded Rigel Pharmaceuticals, a publicly traded company, in 1996. In 2001 he co-founded Telegraph Hill Partners, a San Francisco life sciences private equity firm as a General Partner. Dr. Raffin has been a director of the following Telegraph Hill Partners private portfolio companies: AngioScore, Confirma, Freedom Innovations, LDR Holding Corporation, Magstim and PneumRx; and he has worked closely with Estech and Vidacare. Dr. Raffin received a B.A. from Stanford University and an M.D. from Stanford University School of Medicine and did his medical residency at the Peter Bent Brigham Hospital now Brigham and Women's Hospital in Boston, MA.
- Ernest J. Talarico, III
-
Ernest J. Talarico, III，1999年起担任本公司董事。他从1998年起任职于Mesirow Financial Holdings，这是总部在伊利诺斯州芝加哥的多元化的金融服务公司；他从2008年6月起，担任其总经理。成为总经理之前，2005-2008，他担任高级副总裁；2003-2005，担任副总裁；1998-2003，担任投资经理人员。他专业为个人和公司客户提供财务规划、资产配置及其它财务积累与保本策略。他是一些机构的董事会和委员会成员，其中包括Mesirow Financial的共同基金委员会、精选咨询委员会。他曾担任Cystic Fibrosis Foundation当地分会的主席，也是Talarico Ataxia Foundation的创始人、主席。他获得了University of Iowa的学士学位，持有从事股票、期权与管理式期货的执照。
Ernest J. Talarico, III has served as a member of our Board since 1999. Mr. Talarico has worked for Mesirow Financial Holdings, Inc., a diversified financial services firm headquartered in Chicago, Illinois since 1998 where he has been a Senior Managing Director since December 2015. Prior to becoming Senior Managing Director, Mr. Talarico served as Managing Director from 2008 to 2015 Senior Vice President from 2005 to 2008 Vice President from 2003 to 2005 and Investment Executive from 1998 to 2003. Mr. Talarico specializes in financial planning and asset allocation, as well as other wealth accumulation and preservation strategies for individuals and businesses. Mr. Talarico has been named one of Chicago Magazine’s Five Star Wealth Managers for seven years in a row as selected through an independent survey to identify Chicagoland wealth managers who scored the highest in overall client satisfaction. Mr. Talarico sits on several boards and committees, including the Select Advisory Board and Committee and the Retirement Plan Advisory Investment Committee at Mesirow Financial and Benevolent Enabler, Inc., and the Advisory Board of Catholic Charities for the Archidiocese of Chicago. Mr. Talarico is also the Founder and Chairman of the Talarico Ataxia Open. Mr. Talarico holds a bachelor's degree from the University of Iowa as well as licenses in equities and options. - Ernest J. Talarico, III，1999年起担任本公司董事。他从1998年起任职于Mesirow Financial Holdings，这是总部在伊利诺斯州芝加哥的多元化的金融服务公司；他从2008年6月起，担任其总经理。成为总经理之前，2005-2008，他担任高级副总裁；2003-2005，担任副总裁；1998-2003，担任投资经理人员。他专业为个人和公司客户提供财务规划、资产配置及其它财务积累与保本策略。他是一些机构的董事会和委员会成员，其中包括Mesirow Financial的共同基金委员会、精选咨询委员会。他曾担任Cystic Fibrosis Foundation当地分会的主席，也是Talarico Ataxia Foundation的创始人、主席。他获得了University of Iowa的学士学位，持有从事股票、期权与管理式期货的执照。
- Ernest J. Talarico, III has served as a member of our Board since 1999. Mr. Talarico has worked for Mesirow Financial Holdings, Inc., a diversified financial services firm headquartered in Chicago, Illinois since 1998 where he has been a Senior Managing Director since December 2015. Prior to becoming Senior Managing Director, Mr. Talarico served as Managing Director from 2008 to 2015 Senior Vice President from 2005 to 2008 Vice President from 2003 to 2005 and Investment Executive from 1998 to 2003. Mr. Talarico specializes in financial planning and asset allocation, as well as other wealth accumulation and preservation strategies for individuals and businesses. Mr. Talarico has been named one of Chicago Magazine’s Five Star Wealth Managers for seven years in a row as selected through an independent survey to identify Chicagoland wealth managers who scored the highest in overall client satisfaction. Mr. Talarico sits on several boards and committees, including the Select Advisory Board and Committee and the Retirement Plan Advisory Investment Committee at Mesirow Financial and Benevolent Enabler, Inc., and the Advisory Board of Catholic Charities for the Archidiocese of Chicago. Mr. Talarico is also the Founder and Chairman of the Talarico Ataxia Open. Mr. Talarico holds a bachelor's degree from the University of Iowa as well as licenses in equities and options.
- Paul R. Edick
-
Paul R. Edick是我们的首席执行官，自2010年7月以来我们的董事会成员。他从2008年到2010年担任GANIC Pharmaceuticals, Inc.的首席执行官。从2006年到2008年他担任MedPointe Inc.的首席执行官（在它被Meda AB收购之前）。他还担任Newlink Genetics Corporation和Circassia Inc.的董事会成员。他从2008年到2011年担任LifeCycle Pharma A/S的董事会主席。他持有纽约克林顿Hamilton College的心理学学士学位。
Paul R. Edick,was first appointed a director of the Company in September 2015. Since January 2017 Mr. Edick has served as President and Chief Executive Officer and a director of Xeris Pharmaceuticals, Inc., a private biotechnology company. Since July 2007 he is also managing partner of 3G Advisors, LLC, a consultancy to the pharmaceutical, healthcare and healthcare investor communities. From July 2010 to November 2014 Mr. Edick served as chief executive officer and a board member of Durata Therapeutics, Inc. Prior to his term at Durata, Mr. Edick was chief executive officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus investment search vehicle, from March 2008 to June 2010 and prior to that was chief executive officer at MedPointe Healthcare, Inc., a position he assumed in 2006 having been their president of pharmaceutical operations since April 2002. He also held a number of senior positions at GD Searle & Company, and at Pharmacia Corporation following its acquisition of the company, culminating in his appointment as Pharmacia’s group vice president and president, Asia Pacific/Latin America. Mr. Edick holds a B.A. in Psychology from Hamilton College. In the past, he served on the Boards of Directors for Amerita, Inc., Veloxis Pharmaceuticals A/S and Informed Medical Communications, Inc. Currently, Mr. Edick serves on the Boards of Directors for Neos Therapeutics, Inc., Sucampo Pharmaceuticals, Inc. and NewLink Genetics Corporation, all of which are public companies. He also serves on the Board of Directors of the private company Iterum Therapeutics Ltd. - Paul R. Edick是我们的首席执行官，自2010年7月以来我们的董事会成员。他从2008年到2010年担任GANIC Pharmaceuticals, Inc.的首席执行官。从2006年到2008年他担任MedPointe Inc.的首席执行官（在它被Meda AB收购之前）。他还担任Newlink Genetics Corporation和Circassia Inc.的董事会成员。他从2008年到2011年担任LifeCycle Pharma A/S的董事会主席。他持有纽约克林顿Hamilton College的心理学学士学位。
- Paul R. Edick,was first appointed a director of the Company in September 2015. Since January 2017 Mr. Edick has served as President and Chief Executive Officer and a director of Xeris Pharmaceuticals, Inc., a private biotechnology company. Since July 2007 he is also managing partner of 3G Advisors, LLC, a consultancy to the pharmaceutical, healthcare and healthcare investor communities. From July 2010 to November 2014 Mr. Edick served as chief executive officer and a board member of Durata Therapeutics, Inc. Prior to his term at Durata, Mr. Edick was chief executive officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus investment search vehicle, from March 2008 to June 2010 and prior to that was chief executive officer at MedPointe Healthcare, Inc., a position he assumed in 2006 having been their president of pharmaceutical operations since April 2002. He also held a number of senior positions at GD Searle & Company, and at Pharmacia Corporation following its acquisition of the company, culminating in his appointment as Pharmacia’s group vice president and president, Asia Pacific/Latin America. Mr. Edick holds a B.A. in Psychology from Hamilton College. In the past, he served on the Boards of Directors for Amerita, Inc., Veloxis Pharmaceuticals A/S and Informed Medical Communications, Inc. Currently, Mr. Edick serves on the Boards of Directors for Neos Therapeutics, Inc., Sucampo Pharmaceuticals, Inc. and NewLink Genetics Corporation, all of which are public companies. He also serves on the Board of Directors of the private company Iterum Therapeutics Ltd.
- Lota S. Zoth
-
Lota S. Zoth， 注册会计师。自2012年4月以来，是本公司的一位董事会成员。另外，她是以下上市公司的一位董事会成员：Hyperion Therapeutics股份有限公司和NewLink Genetics公司。在董事会任职之前，她曾于2004年4月-2007年7月期间，担任MedImmune股份有限公司的高级副总裁和财务总监；以及在2002年8月至2004年4月间，是该公司的财务主管和总会计师。在2002年加入MedImmune之前，她曾在PSINet股份有限公司担任高级副总裁、公司主计长和总会计师；以及在Sodexho Marriott Services股份有限公司担任副总裁、公司主计长和首席会计官。她还曾在Marriott International和PepsiCo股份有限公司担任数个管理职位。她曾是Ernst & Young, LLP的一位审计员。Zoth女士是一位注册会计师。她是从德州理工大学（Texas Tech University）获得她的工商管理学士学位的。
Lota S. Zoth,currently serves as the lead independent director of the publicly traded biopharmaceutical company Zymeworks, Inc. and also serves on the boards of directors of the publicly traded biopharmaceutical companies Lumos Pharma, Inc. and 89bio, Inc. Within the last five years, she also served on the boards of directors of the public companies Spark Therapeutics, Inc. and Orexigen Therapeutics, Inc. (which was granted relief under Chapter 11 of the U.S. Bankruptcy Code in 2019). Prior to her board service, she served in senior financial roles in a variety of commercial-stage companies, including serving as MedImmune Inc.'s corporate controller from 2002 to 2004 and its chief financial officer from 2004 until its acquisition by AstraZeneca in 2007. Prior to joining MedImmune in 2002, Ms. Zoth served in financial executive roles at PSINet Inc., Sodexho Marriott Services, Inc., Marriott International and PepsiCo, Inc. Ms. Zoth also served as an auditor at Ernst & Young, LLP and is a Certified Public Accountant. Ms. Zoth holds a B.B.A. in accounting from Texas Tech University. - Lota S. Zoth， 注册会计师。自2012年4月以来，是本公司的一位董事会成员。另外，她是以下上市公司的一位董事会成员：Hyperion Therapeutics股份有限公司和NewLink Genetics公司。在董事会任职之前，她曾于2004年4月-2007年7月期间，担任MedImmune股份有限公司的高级副总裁和财务总监；以及在2002年8月至2004年4月间，是该公司的财务主管和总会计师。在2002年加入MedImmune之前，她曾在PSINet股份有限公司担任高级副总裁、公司主计长和总会计师；以及在Sodexho Marriott Services股份有限公司担任副总裁、公司主计长和首席会计官。她还曾在Marriott International和PepsiCo股份有限公司担任数个管理职位。她曾是Ernst & Young, LLP的一位审计员。Zoth女士是一位注册会计师。她是从德州理工大学（Texas Tech University）获得她的工商管理学士学位的。
- Lota S. Zoth,currently serves as the lead independent director of the publicly traded biopharmaceutical company Zymeworks, Inc. and also serves on the boards of directors of the publicly traded biopharmaceutical companies Lumos Pharma, Inc. and 89bio, Inc. Within the last five years, she also served on the boards of directors of the public companies Spark Therapeutics, Inc. and Orexigen Therapeutics, Inc. (which was granted relief under Chapter 11 of the U.S. Bankruptcy Code in 2019). Prior to her board service, she served in senior financial roles in a variety of commercial-stage companies, including serving as MedImmune Inc.'s corporate controller from 2002 to 2004 and its chief financial officer from 2004 until its acquisition by AstraZeneca in 2007. Prior to joining MedImmune in 2002, Ms. Zoth served in financial executive roles at PSINet Inc., Sodexho Marriott Services, Inc., Marriott International and PepsiCo, Inc. Ms. Zoth also served as an auditor at Ernst & Young, LLP and is a Certified Public Accountant. Ms. Zoth holds a B.B.A. in accounting from Texas Tech University.
高管简历
中英对照 | 中文 | 英文- John B. Henneman, III
John B. Henneman, III，自2019年8月起担任Aprea Therapeutics, Inc.的董事会成员。从2018年7月至2018年11月，Henneman先生担任生物技术公司NewLink Genetics Corporation（“NewLink”）的首席行政官。2014年10月至2018年7月，Henneman先生担任NewLink的执行副总裁兼首席财务官。从1998年到2014年，Henneman先生担任Integra LifeSciences Holdings Corporation（“Integra”）（一家上市的医疗设备公司）的各种职务。在2007年成为Integra的首席财务官之前，Henneman先生是首席行政官，负责Integra的法规事务、质量体系、临床事务、人力资源、信息系统和法律事务职能、Integra手术器械业务的管理以及Integra的业务发展职能。他目前担任R1 RCM公司（一家公开持有的收入周期技术和管理服务公司）、Orthofix Medical公司（一家公开持有的医疗技术公司）、Anika Therapeutics公司（一家公开持有的医疗技术公司）和Alafair Biosciences公司（一家私人持有的医疗设备公司）的董事会成员。他也是Prettybrook Partners（私募股权公司）的高级顾问，以及SparkMed Advisors LLC（为初创医疗设备和生物技术公司提供咨询和其他服务）的顾问。
John B. Henneman, III,has been a member of Board of Aprea Therapeutics, Inc. since August 2019. From July 2018 until November 2018, Mr. Henneman served as the Chief Administrative Officer of NewLink Genetics Corporation ("NewLink"), a biotechnology company. From October 2014 to July 2018, Mr. Henneman served as NewLink's Executive Vice President and Chief Financial Officer. From 1998 to 2014, Mr. Henneman served at Integra LifeSciences Holdings Corporation ("Integra"), a publicly-held medical device company, in various capacities. Before becoming Integra's Chief Financial Officer in 2007, Mr. Henneman was Chief Administrative Officer, responsible for Integra's regulatory affairs, quality systems, clinical affairs, human resources, information systems and legal affairs functions, the management of Integra's surgical instruments business, and Integra's business development function. Mr. Henneman currently serves on the boards of directors of R1 RCM Inc., a publicly-held revenue cycle technology and management services company, Orthofix Medical, Inc., a publicly-held medical technology company, Anika Therapeutics, Inc., a publicly held medical technology company and Alafair Biosciences, Inc., a privately-held medical device company. Mr. Henneman is also senior advisor to Prettybrook Partners, a private equity firm, and a consultant with SparkMed Advisors LLC, which provides consulting and other services to start-up medical device and biotechnology companies.- John B. Henneman, III，自2019年8月起担任Aprea Therapeutics, Inc.的董事会成员。从2018年7月至2018年11月，Henneman先生担任生物技术公司NewLink Genetics Corporation（“NewLink”）的首席行政官。2014年10月至2018年7月，Henneman先生担任NewLink的执行副总裁兼首席财务官。从1998年到2014年，Henneman先生担任Integra LifeSciences Holdings Corporation（“Integra”）（一家上市的医疗设备公司）的各种职务。在2007年成为Integra的首席财务官之前，Henneman先生是首席行政官，负责Integra的法规事务、质量体系、临床事务、人力资源、信息系统和法律事务职能、Integra手术器械业务的管理以及Integra的业务发展职能。他目前担任R1 RCM公司（一家公开持有的收入周期技术和管理服务公司）、Orthofix Medical公司（一家公开持有的医疗技术公司）、Anika Therapeutics公司（一家公开持有的医疗技术公司）和Alafair Biosciences公司（一家私人持有的医疗设备公司）的董事会成员。他也是Prettybrook Partners（私募股权公司）的高级顾问，以及SparkMed Advisors LLC（为初创医疗设备和生物技术公司提供咨询和其他服务）的顾问。
- John B. Henneman, III,has been a member of Board of Aprea Therapeutics, Inc. since August 2019. From July 2018 until November 2018, Mr. Henneman served as the Chief Administrative Officer of NewLink Genetics Corporation ("NewLink"), a biotechnology company. From October 2014 to July 2018, Mr. Henneman served as NewLink's Executive Vice President and Chief Financial Officer. From 1998 to 2014, Mr. Henneman served at Integra LifeSciences Holdings Corporation ("Integra"), a publicly-held medical device company, in various capacities. Before becoming Integra's Chief Financial Officer in 2007, Mr. Henneman was Chief Administrative Officer, responsible for Integra's regulatory affairs, quality systems, clinical affairs, human resources, information systems and legal affairs functions, the management of Integra's surgical instruments business, and Integra's business development function. Mr. Henneman currently serves on the boards of directors of R1 RCM Inc., a publicly-held revenue cycle technology and management services company, Orthofix Medical, Inc., a publicly-held medical technology company, Anika Therapeutics, Inc., a publicly held medical technology company and Alafair Biosciences, Inc., a privately-held medical device company. Mr. Henneman is also senior advisor to Prettybrook Partners, a private equity firm, and a consultant with SparkMed Advisors LLC, which provides consulting and other services to start-up medical device and biotechnology companies.
- Charles J. Link, Jr.
Charles J. Link, Jr.，1999年创办NewLink Genetics Corporation，并担任董事长、首席科学官。2001-2009，他担任其总裁；2003年起，担任首席执行官。他从2005年起，担任BioProtection Systems Corporation的总裁、首席执行官；2005-2009，担任首席科学官。1995-2013，他是Medical Oncology and Hematology Associates of Iowa的执业肿瘤科医生。1995-2003，他担任John Stoddard Cancer Research Institute的主任，他是该机构的联合创始人。1988-1991，他是National Cancer Institute（NCI）和National Institutes of Health（NIH）的医学肿瘤临床研究员。1977-1980，他就读于U.S. Air Force Academy。他获得了Stanford University的学士学位、Stanford University School of Medicine的医学博士学位；他是American Board of Internal Medicine注册的内科医生，之前注册为肿瘤医学。
Charles J. Link, Jr., M.D., founded NewLink Genetics Corporation in 1999 and has served as Chairman of Lumos Pharma, Inc. Board and Lumos Pharma, Inc.Chief Scientific Officer since inception in 1999.He served as President from 2001 to 2009 and has served as Chief Executive Officer since 2003.From 1995 to 2013 Dr. Link was a practicing oncologist at the Medical Oncology and Hematology Associates of Iowa.From 1995 to 2003 Dr. Link served as the Director of the John Stoddard Cancer Research Institute, which he co-founded.Dr. Link served as a Medical Oncology Clinical Fellow at the National Cancer Institute and National Institutes of Health from 1988 to 1991.Dr. Link attended the U.S. Air Force Academy from 1977 to 1980.Dr. Link holds a B.A. from Stanford University, an M.D. from Stanford University School of Medicine and is certified in Internal Medicine by the American Board of Internal Medicine and has previously been certified in Medical Oncology.- Charles J. Link, Jr.，1999年创办NewLink Genetics Corporation，并担任董事长、首席科学官。2001-2009，他担任其总裁；2003年起，担任首席执行官。他从2005年起，担任BioProtection Systems Corporation的总裁、首席执行官；2005-2009，担任首席科学官。1995-2013，他是Medical Oncology and Hematology Associates of Iowa的执业肿瘤科医生。1995-2003，他担任John Stoddard Cancer Research Institute的主任，他是该机构的联合创始人。1988-1991，他是National Cancer Institute（NCI）和National Institutes of Health（NIH）的医学肿瘤临床研究员。1977-1980，他就读于U.S. Air Force Academy。他获得了Stanford University的学士学位、Stanford University School of Medicine的医学博士学位；他是American Board of Internal Medicine注册的内科医生，之前注册为肿瘤医学。
- Charles J. Link, Jr., M.D., founded NewLink Genetics Corporation in 1999 and has served as Chairman of Lumos Pharma, Inc. Board and Lumos Pharma, Inc.Chief Scientific Officer since inception in 1999.He served as President from 2001 to 2009 and has served as Chief Executive Officer since 2003.From 1995 to 2013 Dr. Link was a practicing oncologist at the Medical Oncology and Hematology Associates of Iowa.From 1995 to 2003 Dr. Link served as the Director of the John Stoddard Cancer Research Institute, which he co-founded.Dr. Link served as a Medical Oncology Clinical Fellow at the National Cancer Institute and National Institutes of Health from 1988 to 1991.Dr. Link attended the U.S. Air Force Academy from 1977 to 1980.Dr. Link holds a B.A. from Stanford University, an M.D. from Stanford University School of Medicine and is certified in Internal Medicine by the American Board of Internal Medicine and has previously been certified in Medical Oncology.
- Nicholas N. Vahanian
Nicholas N. Vahanian，NewLink Genetics Corporation的创始人之一，在临床试验设计和药物开发方面有着丰富的经验。2009年起，他担任本公司的总裁、首席医务官；此前，曾担任首席运营官。他是BioProtection Systems Corporation的联合创始人之一，曾担任其首席医务官。他领导了超急性胰脏胰腺癌新药疫苗项目，其中包括IMPRESS试验，这是美国史上胰腺癌切除患者辅助治疗研究的最大规模的试验。他在National Cancer Institute （NCI）开始研究工作，后来任职于National Center for Human Genome Research Institute和 National Institute of Health。他曾就读于St Bartholomew’s 和 Royal London Hospital Medical College，获得了医学学位；后来在John Stoddard Cancer Research Institute完成了分子肿瘤学研究员工作。他获得了Virginia Commonwealth University的生物学学士学位、University of Notre Dame的工商管理硕士学位。
Nicholas N. Vahanian a co-founder of our Company, has served as President and Chief Medical Officer of our Company since 2009 and previously served as Chief Operations Officer. Dr. Vahanian began his research career at the National Cancer Institute and subsequently worked at the National Center for Human Genome Research Institute, National Institute of Health. He attended St Bartholomew’s and Royal London Hospital Medical College and earned his Medical Degree and subsequently completed a Molecular Oncology Fellowship at the John Stoddard Cancer Research Institute. Dr. Vahanian holds a B.S. in Biology from Virginia Commonwealth University and an MBA from the University of Notre Dame.- Nicholas N. Vahanian，NewLink Genetics Corporation的创始人之一，在临床试验设计和药物开发方面有着丰富的经验。2009年起，他担任本公司的总裁、首席医务官；此前，曾担任首席运营官。他是BioProtection Systems Corporation的联合创始人之一，曾担任其首席医务官。他领导了超急性胰脏胰腺癌新药疫苗项目，其中包括IMPRESS试验，这是美国史上胰腺癌切除患者辅助治疗研究的最大规模的试验。他在National Cancer Institute （NCI）开始研究工作，后来任职于National Center for Human Genome Research Institute和 National Institute of Health。他曾就读于St Bartholomew’s 和 Royal London Hospital Medical College，获得了医学学位；后来在John Stoddard Cancer Research Institute完成了分子肿瘤学研究员工作。他获得了Virginia Commonwealth University的生物学学士学位、University of Notre Dame的工商管理硕士学位。
- Nicholas N. Vahanian a co-founder of our Company, has served as President and Chief Medical Officer of our Company since 2009 and previously served as Chief Operations Officer. Dr. Vahanian began his research career at the National Cancer Institute and subsequently worked at the National Center for Human Genome Research Institute, National Institute of Health. He attended St Bartholomew’s and Royal London Hospital Medical College and earned his Medical Degree and subsequently completed a Molecular Oncology Fellowship at the John Stoddard Cancer Research Institute. Dr. Vahanian holds a B.S. in Biology from Virginia Commonwealth University and an MBA from the University of Notre Dame.
- Brian Wiley
Brian Wiley，他曾担任Lumos Pharma, Inc.的首席商务官（2015年以来），此前曾担任其业务发展副总裁（2013年至2015年）。Wiley先生负责Lumos Pharma, Inc.所有投资组合产品的业务开发、商业化和企业沟通策略。在加入the Lumos Pharma, Inc.之前，Wiley先生是Boston BioConsulting, LLC的负责人和创始人，Celgene Corporation & Gloucester Pharmaceuticals的肿瘤学营销高级总监，以及Millennium Pharmaceuticals的肿瘤学营销副总监。从1992年到2004年，他还在安万特/赛诺菲肿瘤公司（Aventis/Sanofi Oncology）担任多个商业化职位，责任越来越大。他持有The Pennsylvania State University的学士学位。
Brian Wiley,has nearly 30 years of experience in the biopharmaceutical industry, with over 25 years dedicated to oncology. His experience includes licensing deals, collaborations, M&A, both public and private financings and multiple product launches in oncology. He founded Boston BioConsulting, LLC, a consulting firm that specializes in corporate strategy, business development and pre-commercial planning for the biopharmaceutical industry. Additionally, he served as Chief Commercial Officer and Head of Business Development at NewLink Genetics and also served in various leadership and management roles at Celgene, Gloucester Pharmaceuticals, Millennium and Aventis.Brian has a B.A. in Marketing from Pennsylvania State University.- Brian Wiley，他曾担任Lumos Pharma, Inc.的首席商务官（2015年以来），此前曾担任其业务发展副总裁（2013年至2015年）。Wiley先生负责Lumos Pharma, Inc.所有投资组合产品的业务开发、商业化和企业沟通策略。在加入the Lumos Pharma, Inc.之前，Wiley先生是Boston BioConsulting, LLC的负责人和创始人，Celgene Corporation & Gloucester Pharmaceuticals的肿瘤学营销高级总监，以及Millennium Pharmaceuticals的肿瘤学营销副总监。从1992年到2004年，他还在安万特/赛诺菲肿瘤公司（Aventis/Sanofi Oncology）担任多个商业化职位，责任越来越大。他持有The Pennsylvania State University的学士学位。
- Brian Wiley,has nearly 30 years of experience in the biopharmaceutical industry, with over 25 years dedicated to oncology. His experience includes licensing deals, collaborations, M&A, both public and private financings and multiple product launches in oncology. He founded Boston BioConsulting, LLC, a consulting firm that specializes in corporate strategy, business development and pre-commercial planning for the biopharmaceutical industry. Additionally, he served as Chief Commercial Officer and Head of Business Development at NewLink Genetics and also served in various leadership and management roles at Celgene, Gloucester Pharmaceuticals, Millennium and Aventis.Brian has a B.A. in Marketing from Pennsylvania State University.